CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net income	$ 248,931	$ 181,385
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	38,115	22,977
Non-cash compensation expense	133,789	142,250
Other non-cash charges and expenses, net	3,956	3,957
Deferred taxes	(40,988)	(79,785)
Changes in assets and liabilites
Increase in Sanofi, Bayer, and trade accounts receivable	(137,928)	(397,428)
Increase in Inventories	(69,744)	(62,263)
(Increase) decrease in prepaid expenses and other assets	(20,325)	39,260
Increase in deferred revenue	12,400	91,205
Increase in accounts payable, accrued expenses and other liabilities	187,695	103,431
Total adjustments	106,970	(136,396)
Net cash provided by operating activities	355,901	44,989
Cash flows from investing activities:
Purchases of marketable securities	(208,694)	0
Sales or maturities of marketable securities	119,012	60,409
Capital expenditures	(50,461)	(104,094)
Net cash used in investing activities	(140,143)	(43,685)
Cash flows from financing activities:
Proceeds in connection with capital and facility lease obligations	57,000	0
Payments in connection with capital and facility lease obligations	(12,861)	(598)
Repayments of convertible senior notes	0	(1,739)
Payments in connection with deduction of outstanding warrants	0	(242,117)
Proceeds from issuance of Common Stock	16,673	39,304
Payments in connection with Common Stock tendered for employee tax obligations	0	(1,042)
Net cash provided by (used in) financing activities	60,812	(206,192)
Net increase (decrease) in cash and cash equivalents	276,570	(204,888)
Cash and cash equivalents at beginning of period	535,203	809,102
Cash and cash equivalents at end of period	$ 811,773	$ 604,214